Therefore, the combination of CDDP and PI3K/mTOR inhibitor could synergistically increase the antitumor efficacy in NPC both in vivo and in vitro (Fig. 5, Fig. 6 A–D and F). The gene discussed is PIK3CA; the disease is nasopharyngeal carcinoma.